NDAORALTABLET
Approved
May 2014
Lifecycle
LOE Approaching
Competitive Pressure
15/100
Data completeness
4/8 — Partial
ZONTIVITY (vorapaxar sulfate) by Passkey Therapeutics. Approved for arteriovenous fistula. First approved in 2014.
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZONTIVITY (vorapaxar sulfate) is an oral protease-activated receptor-1 (PAR-1) antagonist approved in 2014 for arteriovenous fistula, a vascular access complication. The drug works by inhibiting thrombin-induced platelet aggregation to reduce thrombotic events in this specialized vascular indication.
$0.051BPart D
LOE ApproachingDeclining
1.6 years to LOEMinimal commercial footprint with only 88 claims in 2023 signals a niche product with limited field team support and declining revenue trajectory.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Worked on ZONTIVITY at Passkey Therapeutics? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.